Form D · Biotechnology
Aortica Corp
Bellevue, WA · CIK 0001626298
Offering snapshot reported Jun 27, 2017 · SEC filing
- Reported sold
- $1.03M Offering amount: $4M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 13, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 27, 2017 | Initial | $1,025,000 | No comparison | 11 | SEC filing |
| Nov 24, 2014 | Initial | $6,929,965 | No comparison | 61 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-289467
Source: Form D, filed Jun 27, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Buckman | Director |
| Tom Douthitt | Executive |
| Chad Robins | Director |
| Benjamin Starnes | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11811 N.E. 1st Street, Suite 311
Bellevue, WA, 98005
Bellevue, WA, 98005